Form 4 for KLRA Kailera Therapeutics, Inc.
Accepted 2026-06-11 16:05:10 ET · period of report 2026-06-09 · accession 0001193125-26-267493 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-11 16:05 | 2026-06-09 | KLRA | Renaud Ronald C JR | CEO, Pres, Dir | M - OptEx | $5.25 | +38.1K | 38.1K | New | +$200.0K |
| D | 2026-06-11 16:05 | 2026-06-09 | KLRA | Renaud Ronald C JR | CEO, Pres, Dir | M - OptEx | $0.00 | -38.1K | 817.8K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-09 | M | A | 38,094 | $5.25 | 38,094 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2026-06-09 | M | D | 38,094 | $0.00 | 817,826 | D | $5.25 · — to 2034-09-19 | 38,094 Common Stock | (F1) The options vested and became exercisable as to 33% of the total shares on September 9, 2025 and thereafter in 24 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. |